6-amino-N-isopropyl-N-(3-morpholinopropyl)hexane-1-sulfonamide | 1170232-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 6-amino-N-isopropyl-N-(3-morpholinopropyl)hexane-1-sulfonamide
• 英文别名: 6-amino-N-(3-morpholin-4-ylpropyl)-N-propan-2-ylhexane-1-sulfonamide
• CAS: 1170232-95-7
• 化学式: C₁₆H₃₅N₃O₃S
• 分子量: 349.538
• InChiKey: OKYUSJCXORTTRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  23
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] NOVEL CYANOGUANIDINES<br/>[FR] NOUVELLES CYANOGUANIDINES
  申请人：TOPOTARGET AS

  公开号：WO2009086835A1

  公开（公告）日：2009-07-16

  This application discloses novel cyanoguanidines of the formula (I) wherein A is selected from -C(=O)-, -S(=O)2-, -C(=S)-, and -P(=O)(R5)-, wherein R5 is selected from C1-6-alkyl, C1-6-alkoxy, and hydroxy; B is selected from a single bond, -O-, -NR6- and -C(=O)-NR6-, wherein R6 is selected from hydrogen, optionally substituted C1-12-alkyl, optionally substituted C1-12-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and m is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20; and R1 is selected from optionally substituted heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT).

  该申请公开了一种新型氰胍啶化合物，其化学式为（I），其中A从-C（=O）-，-S（=O）2-，-C（=S）-和-P（=O）（R5）-中选择，其中R5选择自C1-6-烷基，C1-6-烷氧基和羟基；B从单键，-O-，-NR6-和-C（=O）-NR6-中选择，其中R6选择自氢，可选择地取代的C1-12-烷基，可选择地取代的C1-12-烯基，可选择地取代的芳基，可选择地取代的杂环烷基和可选择地取代的杂环芳基；m为0-12的整数，n为0-12的整数，其中m+n之和为1-20；R1选择自可选择地取代的杂环芳基；以及其药学上可接受的盐和前药。这些化合物可用作治疗由烟酰胺磷酸核糖转移酶（NAMPRT）水平升高引起的疾病或病况的药物。
• NOVEL UREA AND THIOUREA DERIVATIVES
  申请人：Christensen Mette Knak

  公开号：US20120010172A1

  公开（公告）日：2012-01-12

  The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O) 2 —, —C(═S)— and P(═O)(R 5 )—; B is, —O—, —(CH 2 ) 3-6 —, and O—(CH 2 ) 2-5 —; D is, —O—, —CR 7 R 8 — and —NR 9 ; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R 1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.
• NOVEL UREA AND THIOUREA DERIVATIVES
  申请人：TOPOTARGET A/S

  公开号：US20140357599A1

  公开（公告）日：2014-12-04

  The present application discloses compounds of formula (I) wherein X is ═O, ═S, ═NH, ═NOH and ═NO-Me; A is —C(═O)—, —S(═O) 2 —, —C(═S)— and P(═O)(R 5 )—; B is, —O—, —(CH 2 ) 3-6 —, and O—(CH 2 ) 2-5 —; D is, —O—, —CR 7 R 8 — and —NR 9 ; m is 0-12, n is 0-12, m+n is 1-20; p is 0-4; R 1 is opt.sub. heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The application also discloses the compound for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT), e.g. inflammatory and tissue repair disorders; dermatosis; autoimmune diseases, Alzheimers disease, stroke, athersclerosis, restenosis, diabetes, glomerulonephritis, cancer, cachexia, inflammation associated with infection and certain viral infections, including Acquired Immune Deficiency Syndrome (AIDS), adult respiratory distress syndrome, ataxia telengiectasia.
• US8871747B2
  申请人：——

  公开号：US8871747B2

  公开（公告）日：2014-10-28